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ABSTRACT
The chemokine-like peptide, chemerin, stimulates chemotaxis in several cell 
types. In this study we examined the expression of putative chemerin receptors 
in gastric cancer and the action of chemerin on cancer cell migration and invasion. 
Immunohistochemical studies of gastric tumors identified expression of two putative 
receptors, chemokine-like receptor-1 (CMKLR1) and G-protein coupled receptor 
1(GPR1), in cancer cells; there was also some expression in stromal myofibroblasts 
although generally at a lower intensity. The expression of both receptors was 
detected in a gastric cancer cell line, AGS; chemerin itself was expressed in 
cultured gastric cancer myofibroblasts but not AGS cells. Chemerin stimulated (a) 
morphological transformation of AGS cells characterized by extension of processes 
and cell scattering, (b) migration in scratch wound assays and (c) both migration 
and invasion in Boyden chamber chemotaxis assays. These responses were inhibited 
by two putative receptor antagonists CCX832 and α-NETA. Inhibition of receptor 
expression by siRNA selectively reduced CMKLR1 or GPR1 and inhibited the action 
of chemerin indicating that both receptors contributed to the functional response. 
Using a proteomic approach employing stable isotope dynamic labeling of secretomes 
(SIDLS) to selectively label secreted proteins, we identified down regulation of tissue 
inhibitors of metalloproteinease (TIMP)1 and TIMP2 in media in response to chemerin. 
When cells were treated with chemerin and TIMP1 or TIMP2 the migration response 
to chemerin was reduced. The data suggest a role for chemerin in promoting the 
invasion of gastric cancer cells via CMKLR1 and GPR1at least partly by reducing TIMP1 
and TIMP2 expression. Chemerin receptor antagonists have potential in inhibiting 
gastric cancer progression.
INTRODUCTION
Gastric cancer is considered to be the second 
commonest cause of cancer mortality worldwide [1]. Early 
detection favours survival but nevertheless the prognosis 
is dismal for most patients with 5 year survival in many 
parts of the world of about 20% [2]. It is well established 
that infection with Helicobacter pylori carries an increased 
risk of gastric cancer but progression occurs over many 
decades following a well document sequence of chronic 
inflammation, atrophy, metaplasia and dysplasia [3, 4]. 
While genetic, dietary and environmental factors may all 
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play a role in those patients who do progress to cancer, 
the mechanisms promoting tumor invasion and metastasis 
remain incompletely understood.
It is now well recognised that in solid tumors 
there are interplays between cancer cells and stromal 
cells that strongly influence the disease process [5]. In 
particular, cancer cell growth depends on the appropriate 
microenvironment which in turn is determined by non-
neoplastic stromal cells. There are important roles for 
immune and angiogenic cells [6]; but in addition cells of 
fibroblastic lineages are now seen as key contributors to 
the tumor microenvironment [7]. Functional differences 
between normal and cancer-associated fibroblasts are 
recognised to underpin the role of the latter in promoting 
tumor growth. Myofibroblasts are an important subset of 
fibroblasts and differences in gene expression, protein 
secretion, miRNA profiles, DNA methylation, cell 
proliferation and motility have all been described for 
cancer-associated myofibroblasts (CAMs) compared 
with normal tissue myofibroblasts or cancer adjacent 
tissue myofibroblasts [8–11]. In the case of squamous 
esophageal cancer, the chemokine-like peptide chemerin 
has recently been described as upregulated in CAMs and 
to stimulate esophageal cancer cell invasion [12, 13].
Chemerin (also known as tazarotene induced gene 
2, TIG2; retinoic acid receptor responder 2, RARRES2) 
is an 18kDa protein, which is cleaved in the C-terminal 
region to generate an active product [14]. It is quite widely 
expressed in liver, placenta and adipocytes. Two putative 
functional receptors have been identified: CMKLR1 (also 
known as ChemR23, TIG2 receptor) and GPR1 [14–
17]; chemokine receptor-like 2 (CCRL2) may also bind 
chemerin and aid in its presentation to CMKLR1 [18, 
19]. There have been reports that chemerin is increased 
in blood in gastric cancer patients [20]. Moreover, the 
extensively used gastric cancer cell line, AGS, has been 
reported to express chemerin receptors and respond to 
chemerin by increased migration [20, 21]. However, 
the expression of receptors in primary gastric cancers is 
largely unexplored and understanding of the mechanism 
of action of chemerin in this condition is still at an early 
stage. We now report that both CMKLR1 and GPR1 are 
expressed in gastric cancer and in AGS cells, and both 
mediate migratory and invasive responses. Interestingly, 
a proteomic study identified down-regulation of tissue 
inhibitors of metalloproteinases (TIMPs) as potentially 
implicated in the migratory response.
RESULTS
Expression of chemerin receptors in gastric 
cancer
Immunohistochemical studies on 15 patients with 
gastric cancer revealed CMKLR1 at high intensity in 
virtually all cancer cells (Figure 1A) with no obvious 
differences between intestinal, diffuse or mixed gastric 
cancers, or TNM stage. There was also expression 
in spindle-shaped stromal cells, consistent with a 
myofibroblast phenotype; the intensity of staining of 
stromal cells was greatest in those cells adjacent to tumor 
cells (Figure 1A, centre panel) compared with those that 
were distant (Figure 1A, right). There was also expression 
of GPR1 in most cancer cells although the intensity of 
staining was lower than CMKLR1; moreover, GPR1 
was also expressed in myofibroblasts particularly those 
adjacent to tumor cells (Figure 1B).
Chemerin mediates myofibroblast chemotactic 
effects on cancer cells
To establish whether chemerin is a potential 
mediator of stromal-cancer cell interactions in gastric 
cancer, as in esophageal squamous cancer [13], we 
sought evidence by western blot for chemerin expression 
in gastric myofibroblasts: two different gastric CAMs 
secreted chemerin into the medium while the cancer cell 
line, AGS, did not (Figure 2A). Evidence that CAMs 
secrete chemerin in functionally relevant concentrations 
was indicated by the observation that conditioned medium 
from gastric CAMs stimulated AGS cell migration in 
Boyden chamber experiments, and the effects were 
inhibited by two chemerin receptor antagonists, CCX832 
and α-NETA (Figure 2B).
Chemerin stimulates morphological 
transformation of AGS cells
To directly examine the effects of chemerin on 
gastric cancer cells, we then treated sub-confluent AGS 
cells with chemerin. Over a period of 7 h chemerin-treated 
AGS cells exhibited a morphological transformation 
characterized by extension of processes and cell scattering 
(Figure 3A). Quantification of transformed cells revealed 
a concentration-dependent response that was almost 
completely inhibited by α-NETA at 5 μM, and was 
significantly inhibited by CCX832 at 1μM (Figure 3B 
and 3C). There is a similar transformation, which has 
been characterised as epithelial-mesenchymal transition 
(EMT), in response to gastrin which is protein kinase C 
(PKC) mediated [22]; in the present study inhibition of 
PKC using Ro-320432 also abolished the transformation 
in response to chemerin (Figure 3D).
Chemerin stimulates AGS cell migration and 
invasion
In order to examine the migratory response to 
chemerin in more detail we first used scratch wound 
assays (Figure 4A). These showed increased migration 
in response to both chemerin and phorbol 12-myristate 
13-acetate (PMA) (Figure 4B); the effect of chemerin 
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was inhibited by 1 μM CCX832 (Figure 4C), 5 μM 
α-NETA (Figure 4D) and 1 μM Ro-320432 (Figure 4E). 
The specificity of action of CCX832 and α-NETA was 
indicated by the fact that increased migration in response 
to PMA was not inhibited CCX832 or α-NETA (Figure 
4F and 4G). Similarly, in Boyden chamber chemotaxis 
migration (Figure 4H) and invasion (Figure 4I) assays 
there was also a strong response to chemerin that was 
significantly inhibited by CCX832 and α-NETA.
Both CMKLR1 and GPR1 mediate the effect of 
chemerin
We then examined the role of the two putative 
receptors by their selective knockdown in AGS cells. 
Immunohistochemistry identified both CMKLR1 and 
GPR1 in virtually all AGS cells (Figure 5A). Treatment 
of cells with siRNA for CMKLR1 reduced the number 
of cells expressing the receptor by approximately 75%, 
Figure 1: Expression of CMKLR1 and GPR1 in gastric cancer. (A) Immunohistochemical localization of CMKLR1 in gastric 
tumors (top panels) and quantification in lower panels based on the proportion of cells in each compartment scored 0 – 3 for intensity; 
left, cancer cells; centre, stromal cells close to tumor cells (proximal); right, stromal cells distal to tumor cells (distal). (B) Similar data for 
GPR1. Bar graphs show data for 15 patients, mean ± S.E.
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but did not change the proportion of cells expressing 
GPR1; conversely, siRNA inhibition of GPR1 reduced 
the proportion of cells expressing the receptor by 
approximately 60% but did not change the expression 
of CMKLR1 (Figure 5A). In Boyden chamber migration 
assays, selective knockdown of CMKLR1 and GPR1 
significantly inhibited the response to chemerin, although 
in each case it was not completely suppressed (Figure 5B). 
The response to PMA which was run as a positive control 
was not influenced by receptor knockdown (Figure 5B). 
Similarly, in invasion assays, siRNA knockdown of both 
receptors inhibited but did not abolish the response to 
chemerin, while that to PMA was unaffected (Figure 5C). 
When siRNA knockdown of both receptors was performed 
simultaneously there was virtually complete inhibition of 
both migration and invasion responses (Figure 5D).
Stable isotope dynamic labeling of secretomes 
(SIDLS) identification of secreted proteins in 
chemerin-treated AGS cells
We then employed a proteomic approach (SIDLS) 
to identify changes in secretome proteins that were 
potentially relevant to the actions of chemerin described 
above. Proteomic studies of cell media frequently 
identify both authentic secretory proteins and intracellular 
proteins released by cell damage; because secretory 
proteins turnover more rapidly than intracellular proteins 
a shortened labeling period preferentially labels secretory 
proteins [23, 24]. Thus a total of 1759 proteins were 
identified of which 240 had a labeling (heavy to light 
amino acid) ratio >0.01 indicating a degree of preferential 
labeling. As an independent check on the identification of 
secretory proteins, we then filtered the secretome list by 
searching for classical secretory proteins defined on the 
basis of a SignalP score of >0.5 Of the latter there were 
36 that had been labelled in 2 or more tryptic peptides and 
interestingly the H/L ratios were typically <0.5 in these 
proteins (Table 1) indicating inhibition of expression by 
chemerin.
Analysis of the list of secretomes using Protein 
ANalysis THrough Evolutionary Relationships 
(PANTHER) for significantly enriched (p<0.05) protein 
classes, molecular functions and biological processes, 
identified “protease inhibitor” and “metalloprotease 
inhibitor” as two of the top four of protein classes 
affected. Moreover, “peptidase activity” and “peptidase 
inhibitor activity” were the top ranked molecular function 
identified, and “proteolysis” was the highest ranked 
biological process identified (Figure 6). Amongst specific 
targets, decreased expression of TIMP-1 and TIMP-2 were 
identified as significantly reduced in response to chemerin.
TIMP-1 and TIMP-2 in AGS media are 
depressed by chemerin and inhibit migration 
and invasion
In order to validate the effect of chemerin on TIMP-
1 and TIMP-2 we first showed by western blot that in the 
media of cells treated with chemerin there was depressed 
TIMP-1 and TIMP-2; in contrast there was no change 
in the abundance of matrix metalloproteinase (MMP)-1 
included for reference (Figure 7A, left). In keeping with 
the observation that the effects of chemerin are mediated 
Figure 2: Chemerin mediates myofibroblast effects on AGS cancer cells. (A) Western blot shows expression of chemerin in 
two different gastric cancer-associated myofibroblasts (CAM1 and CAM2) but not AGS cells. (B), Left, conditioned medium from gastric 
CAMs (CAM CM) stimulates migration of AGS cells in Boyden chamber chemotaxis assays and the response is inhibited by CCX832 
(1μM) and α-NETA (5μM); right, similar results for Boyden chamber invasion assays (n=3). Horizontal lines, p<0.05, ANOVA.
Oncotarget102www.oncotarget.com
by PKC, the addition of Ro-320432 reversed the decrease 
in TIMP-1 and TIMP-2 abundance in response to chemerin 
(Figure 7A, right). In migration experiments, restitution 
of TIMP-1 and TIMP-2, by addition of exogenous 
protein, inhibited the response to chemerin (Figure 7B). 
Moreover, in invasion experiments TIMP-1 and TIMP-2 
also inhibited the response to chemerin (Figure 7C).
DISCUSSION
The chemerin/CMKLR1 system is associated with 
stimulation of migration and invasion of a wide variety 
of cells including immune and inflammatory cells, 
mesenchymal stem cells, vascular smooth muscle and 
endothelial cells [12, 14, 25, 26]. The role of GPR1 is less 
well studied. Recently there has been emerging interest in 
the role of this system in promoting cancer cell migration 
and invasion [13, 27]. The present data support the idea 
that gastric adenocarcinoma cells express both CMKLR1 
and GPR1, and that both play a role in mediating the effect 
of chemerin on cancer cell migration and invasion. The 
actions of chemerin appear to be mediated, at least in part, 
by PKC-suppression of TIMP-1 and -2 expression.
The role of chemerin in different types of cancer 
appears to vary. In some cases, chemerin is protective; 
for example, in melanoma it stimulates recruitment of NK 
cells suggesting a role in tumor cell immune evasion [28]; 
and there is evidence of a tumor suppressor function in 
adrenocortical carcinoma and hepatocellular carcinoma 
[29, 30]. Set against this, however, increased chemerin 
expression has been associated with colorectal cancer 
[31], squamous cell carcinoma of the oral tongue [32] 
and stomach cancer [20], while the situation in the case 
of non-small cell lung cancer remains uncertain [33, 34]. 
The data therefore suggest that depending on the tumor 
type, chemerin may be associated with either aggressive 
or protective roles.
The expression in primary tumors of the putative 
receptors, CMKRL1 and GPR1, has been less well 
studied than that of chemerin itself. Previously, primary 
esophageal squamous cancers were shown to express 
CMKLR1 [13]; neuroblastoma cells also express both 
receptors and there is evidence that chemerin acts via 
CMKLR1 in an α-NETA sensitive mechanism to increase 
MMP-2 to promote tumor growth [35]. We now show that 
both CMKLR1 and GPR1 are expressed by primary gastric 
Figure 3: Chemerin induces a morphological transformation of AGS cells. (A) representative images of sub-confluent AGS 
cells showing that chemerin (Chem, 10 nM) induces cell scattering and extension of processes which is reduced by addition of CCX832 
(1μM) and α-NETA (5μM); the latter have no effect alone. (B) Dose-response relationships for the action of chemerin alone in stimulating 
process extension by AGS cells (left) and of graded concentrations of α-NETA in inhibiting the effects of 10 nM chemerin (right). (C) 
Quantitative assessment of the proportion of cells exhibiting extension of processes after treatment with chemerin (10 nM), CCX832 (1μM) 
and Ro-320432 (1 μM); (n=3). Horizontal lines, p<0.05, ANOVA.
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Figure 4: Chemerin stimulated AGS cell migration is inhibited by CCX832 and α-NETA. (A) Representative images 
showing scratch wound assays at 0 and 16 h and effect of chemerin (Chem, 10 nM) and phorbol 12-myristate 13-acetate (PMA, 100 nM) 
compared with control, serum-free (SF) medium. (B) Quantification of migrating cells in a defined area in scratch wound assays in response 
to chemerin and PMA. (C) The action of chemerin in scratch wound assays is inhibited by CCX832 (1 μ), (D) by α-NETA (5 μM) and 
(E), by Ro-320432 (1μM). (F), The action of PMA in scratch wound assays is not inhibited by CCX832, or (G) α-NETA. (H), In Boyden 
chamber chemotaxis migration assays, the effect of chemerin is inhibited by CCX823 and α-NETA; (I) similar data for Boyden chamber 
invasion assays. Horizontal lines, p<0.05 ANOVA.
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Figure 5: CMKLR1 and GPR1 mediate the effects of chemerin on AGS cells. (A) Left, Immunocytochemical localization of 
CMKLR1 and GPR1 on AGS cells and selective knockdown (CMKLR1-KD and GPR1-KD, respectively) by siRNA treatment (arrows, 
positively stained cells); right, quantification of positively stained cells after siRNA knockdown (open bars, proportion of cells exhibiting 
CMKLR1 staining; shaded bars, proportion of cells exhibiting GPR1 staining). (B) Left, representative images from Boyden chamber 
migration experiments after CMKLR1 and GPR1 knockdown (arrows, migrating cells); centre, quantification of migration responses 
to chemerin (Chem, 10 nM) after receptor knockdown; right, quantification of migration responses to PMA (100 nM) after receptor 
knockdown. (C), Left, representative images from Boyden chamber invasion experiments after CMKLR1 and GPR1 knockdown (arrows, 
invading cells); centre, 10 quantification of invasion responses to 10 nM chemerin after receptor knockdown; right, quantification of 
invasion responses to 100 nM PMA after receptor knockdown. (D), Left, Boyden chamber migration responses after double knockdown 
of CMKLR1 and GPR1; right Boyden chamber invasion responses after double knockdown of CMKLR1 and GPR1. Horizontal arrows, 
p<0.05, ANOVA.
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Table 1: Secreted proteins with a differential incorporation of heavy and light isotope. Proteins were filtered on the 
basis of H/L ratio >0.01 and SigP score >0.5. The Table lists name, sub-cellular localisation and H/L ratio
No. Description (Human Proteins) Accession Subcellular Localisation
H:L Ratio Chemerin: 
Control
1 Insulin-like growth factor-binding protein 6 (IBP6) P24592 Secreted 0.35
2 Cathepsin D (CATD) P07339 Secreted 0.314
3 Prosaposin (SAP) P07602 Secreted 0.278
4 Calsyntenin-1 (CSTN1) O94985 Endoplasmic reticulum membrane 0.267
5 Sulfhydryl oxidase 1 (QSOX1) O00391 Secreted 0.256
6 Pro-MCH OS=Homo sapiens (PMCH) P20382 Secreted 0.252
7 Serine protease 23 (PRS23) O95084 Secreted 0.249
8 Metalloproteinase inhibitor 1 (TIMP1) P01033 Secreted 0.229
9 Thrombospondin-1 (TSP1) P07996 Endoplasmic reticulum 0.211
10 Cystatin-C (CYTC) P01034 Secreted 0.21
11 Metalloproteinase inhibitor 2 (TIMP2) P16035 Secreted 0.21
12 Kallikrein-6 (KLK6) Q92876 Secreted 0.209
13 Amyloid beta A4 protein (APP) P05067 Membrane 0.207
14 Trypsin-1 ([TRY1) P07477 Secreted 0.183
15 Cystatin-SN (CYTN) P01037 Secreted 0.181
16 Basement membrane-specific heparan sulfate proteoglycan core protein (PGBM) P98160 Secreted 0.174
17 Agrin (AGRN) O00468 Secreted 0.167
18 Zinc transporter ZIP10 (S39AA) Q9ULF5 Membrane 0.153
19 Growth/differentiation factor 15 (GDF15) Q99988 Secreted 0.15
20 Amyloid-like protein 2 (APLP2) Q06481 Membrane 0.141
21 Dickkopf-related protein 1 (DKK1) O94907 Secreted 0.139
22 Peptidyl-glycine alpha-amidating monooxygenase (AMD) P19021 Membrane/Secreted 0.129
23 Beta-2-microglobulin (B2MG) P61769 Secreted 0.127
24 Dystroglycan (DAG1) Q14118 Secreted 0.122
25 Trypsin-2 (TRY2) P07478 Secreted 0.121
26 Kunitz-type protease inhibitor 1 (SPIT1) O43278 Secreted. 0.108
27 HLA class I histocompatibility antigen, A-2 alpha chain (HLA-A) P01892 Membrane 0.105
28 Dipeptidyl peptidase 1 (CATC) P53634 Lysosome 0.094
29 Disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) Q13443 Secreted 0.074
30 Protein disulfide-isomerase A3 (PDIA3) P30101 Endoplasmic reticulum 0.073
(continued )
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adenocarcinoma cells. Thus in addition, to possible roles 
of chemerin in modifying the tumor microenvironment by 
influencing migration of immune and inflammatory cells 
there is also the potential for direct effects on cancer cell 
invasion or migration. The balance between the effects of 
chemerin on migration/invasion of cancer cells on the one 
hand and immune cells on the other hand, may account 
for the differences between cancer types as to whether 
chemerin has a protective or aggressive role.
Two previous studies have noted increased invasion 
of gastric cancer cells in response to chemerin [20, 21]. 
By selectively inhibiting expression of each receptor 
we conclude that both CMKLR1 and GPR1 mediate the 
effects of chemerin, moreover our findings support a role 
for PKC as a downstream mediator in both cases. The data 
therefore add to previous work implicating the RhoA and 
Rho-associated protein kinase (ROCK) pathway, and other 
kinases in AGS cell responses to chemerin [21]. AGS cells 
are relatively well studied and are arguably the cell line of 
choice for EMT-like responses of gastric adenocarcinoma 
cells; thus, for example, other well studied gastric cancer 
cell lines such as MKN45 cells perform poorly in assays of 
the type used here. It is however, worth noting that we have 
found that in the case of another upper gastrointestinal 
adenocarcinoma cell line, namely esophageal OE33 
cells, there is a 2-fold increase in migration in response 
to chemerin in Boyden chamber assays (unpublished 
observations). It is known that activation of PKC in AGS 
cells leads to an EMT-like phenotype and in this sense the 
response of AGS cells to chemerin resembles that to the 
gastric hormone gastrin which also stimulates migration, 
invasion, morphological transformation via activation 
of multiple pathways including PKC [22, 36]. There 
would now be clear advantages to a systematic study of 
the mechanism of action of chemerin across a range of 
gastrointestinal adenocarcinoma cell lines.
Two putative chemerin receptor antagonists, 
CCX832 [37] and α-NETA [38], have been described. In 
the present study both were able to produce near complete 
inhibition of AGS cell responses to chemerin. In vascular 
cells, CCX832 has been reported to be highly specific 
for CMKLR1 [39], and GPR1 - although expressed - 
was considered to be functionally unimportant. Since 
our siRNA data indicate that both CMKLR1 and GPR1 
mediate the effects of chemerin in AGS cells and since 
both antagonists were capable of inhibiting biological 
responses it seems likely that both are able to act at the 
two receptors. For practical purposes it would seem 
appropriate, therefore, to exercise caution in assigning 
the actions of these compounds to one receptor or the 
other.
The elucidation of secretomes is central to 
an understanding of the dynamics of the tumor 
microenvironment. Early studies in this area using AGS 
cells noted changes in plasminogen activator inhibitor 
(PAI)-2 and PAI-1, and fibroblast growth factor (FGF)2, 
using microarray or proteomic analyses [40, 41]. 
More recently, proteomic and microarray analysis of 
myofibroblast secretomes has identified the importance 
of MMPs and extracellular matrix proteins [8, 42]. Cell 
migration and invasion whether of cancer or stromal 
cells requires dynamic changes in the capacity for 
extracellular protein digestion which in turn reflects a 
balance between the release and activation of proteases, 
particularly members of the MMP family, and their 
inhibitors such as the TIMPs [43]. One of the novel 
findings of the present study is that suppression of 
TIMP-1 and -2 is a downstream response to chemerin 
mediated by PKC.
Gastric cancer remains a devastating disease 
associated with high mortality. Early detection favours 
survival but even so there is a need for new approaches to 
treat progression of the disease. The present study raises 
the possibility that the chemerin system may be a useful 
target for slowing the migration and invasion steps that 
lead to metastasis. The generation of antagonists for two 
of the main chemerin receptors (CMKLR1 and GPR1) 
encourages the idea that it may be feasible to develop 
relevant new therapeutic approaches for the inhibition of 
metastasis in these tumors.
No. Description (Human Proteins) Accession Subcellular Localisation
H:L Ratio Chemerin: 
Control
31 Growth-regulated alpha protein (CXCL1) P09341 Secreted 0.067
32 Midkine (MDK) P21741 Secreted 0.063
33 Interleukin-8 OS=Homo sapiens (CXCL8) P10145 Secreted 0.05
34 Protein disulfide-isomerase (P4HB) P07237 Endoplasmic reticulum 0.047
35 Nucleobindin-1 OS=Homo sapiens (NUCB1) Q02818 Secreted 0.047
36 Calreticulin OS=Homo sapiens (CALR) P27797 Secreted 0.039
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Figure 6: Meta-analysis of SIDLS labeling of the AGS cell secretome identifies proteins involved in inhibition of 
proteolysis as targets of chemerin. Protein ANalysis THrough Evolutionary Relationships (PANTHER) analysis shows, top, enriched 
protein classes; middle, enriched molecular functions; bottom, enriched biological processes. In each case the –log of the probability is 
shown and data for p<0.05 included.
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Figure 7: Chemerin stimulates migration and invasion via suppression of TIMP-1 and TIMP-2. (A) Left, Western analysis 
showing chemerin decreases the abundance of TIMP-1 and TIMP-2, but not MMP-1 in AGS cell media; right, the effect of chemerin is 
inhibited by Ro-320432. (B) The effect of chemerin on AGS cell migration is suppressed by addition of TIMP-1 (left; 2.1 nM) and TIMP-2 
(right; 2.5 nM). (C) Similarly, the effect of chemerin on AGS cell invasion is suppressed by addition of TIMP-1 (left) and TIMP-2 (right). 




Formalin-fixed, paraffin embedded, surgical 
resection material from the gastric tumors of 15 patients 
were used; the characteristics of the patients, including 
TNM staging [44], have previously been described [8]. 
All patients gave informed consent and the study was 
approved by the University of Szeged Ethics Committee.
Cells
Gastric cancer cells (AGS) were obtained from 
American type culture collection (VA, USA). Two 
different gastric CAMs were used that had been generated 
previously and have been described [8, 11]. AGS cells and 
myofibroblasts were cultured as previously described [41, 
45].
Immunohistochemistry
Paraffin embedded sections were processed for 
immunohistochemistry using antigen retrieval and 
stained with rabbit polyclonal antibodies to CMKLR1 
(Millipore, MA, USA) or GPR1 (Abcam, Cambridge, 
UK) as previously described [13]. Stromal and epithelial 
compartments were scored separately for staining 
intensity on a four point scale (0–3) by two independent 
pathologists and the percentage of stained cells at each 
intensity recorded. Controls in which first antibody was 
either omitted or substituted with control rabbit IgG 
yielded negative results (ie scored as 0).
Immunocytochemistry
Cells were formalin-fixed (4% w/v), permeabilised 
with 0.2% Triton X-100 in PBS (PBS-T) for 30 
min at room temperature (RT) and processed for 
immunohistochemistry as previously described [13] 
using antibodies to CMKLR1 (Millipore) or GPR1 
(Abcam) followed by incubation with the appropriate 
fluorescein secondary antibodies raised in donkey 
(Jackson Immunoresearch, Soham, UK), and mounted 
with Vectashield containing DAPI (Vector Laboratories, 
Peterborough, UK). Slides were viewed using a Zeiss 
Axioplan-2 microscope (Zeiss Vision, Welwyn Garden 
City, UK) and images were captured at 40× magnification.
Conditioned media
Two gastric cancer myofibroblasts (1.5 x 106 
cells) were separately plated in T-75 falcon flasks and 
maintained at 37°C in a 5% v/v CO2 atmosphere for 24 
h in FM. Cultures were then washed 3 times with sterile 
PBS and incubated in 15ml serum free (SF) media for 24 
h. Conditioned media were collected, centrifuged (7 min, 
800 x g, 4°C) and aliquots stored at −880°C until further 
use.
Morphological transformation
AGS cells were seeded at a density of 40,000 cells 
per well in 6 well plates and allowed to form colonies of 
an average size of about 30 cells; as described previously 
these conditions yield sub-confluent cultures that are 
optimal for visualization of morphological changes [22]. 
Cell were changed to serum free medium and treated with 
the active C-terminal nonapeptide of chemerin (GeneScipt, 
Piscataway, NJ, USA), phorbol 12-myristate 13-acetate 
(PMA; Sigma, Dorset, UK), Ro-320432 (Sigma), CCX832 
(ChemoCentryx, Mountain View, CA, USA) or α-NETA 
(N,N,N-Trimethyl-γ-oxo-1-naphthalenepropanaminium 
iodide; Sigma), as appropriate. Five fields captured 
at 0 and 7 h were quantified for the proportion of cells 
extending processes, expressed as a percentage.
Cell migration and invasion assays
Scratch wound migration assays were performed on 
confluent monolayers of AGS cells as previously described 
[41]. Transwell migration and invasion chemotaxis assays 
were performed using BD inserts (Corning, NY, USA) as 
previous described (25,000 cells per insert) [46]. Chemerin 
or CAM-conditioned medium (CM) were added in the 
lower well together with CCX832, α-NETA, Ro-320432, 
human recombinant TIMP-1 or TIMP-2 (R&D Systems), 
or vehicle, as appropriate.
CMKLR1 and GPR-1 knockdown
Cells were transiently transfected using Amaxa™ 
Cell line Nucleofector™ kits V using the program T-19 
for high transfection efficiency (Amaxa, Köln, Germany) 
according to manufacturer’s instructions. AGS cells were 
treated with scrambled or validated siRNAs (3μM) for 
CMKLR1 and GPR-1 (Invitrogen, Paisley, UK) [12]. The 
efficiency of knockdown for CMKLR1 and GPR-1 was 
verified by immunocytochemistry.
Proteomic analysis
Putative chemerin targets in the AGS secretome 
were identified using a stable isotope dynamic labeling 
of secretomes (SIDLS) approach based on that recently 
described [23, 24]. Briefly, AGS cells (106 cells, 10cm 
dishes, approximately 70% confluency) were incubated 
with chemerin (10 nM), or not, for 24 h; for the last 6 h the 
medium was changed to one containing either 13C6 lysine 
and 13C6 arginine (heavy label; chemerin), or 
12C6 lysine 
and 12C6 arginine (control, light label), to dynamically 
label secreted proteins. Media were then collected, pooled 
and centrifuged (800 x g, 7 min). StrataClean resin 
(Agilent Technologies Ltd., Wokingham, UK) was used to 
Oncotarget110www.oncotarget.com
capture proteins in media samples prior to tryptic digestion 
as previously described [23] and peptide separation using 
an Ultimate 3000 nano system (Dionex/Thermo Fisher) 
coupled to a Q-Exactive quadrupole Orbitrap mass 
spectrometer (Thermo Fisher). SIDLS data were searched 
and analysed using MaxQuant 1.1.1.36 against the human 
IPI database v3.68 using the recommended default 
settings.
Secreted protein search and GeneOntology 
analsysis
Data were filtered with a FDR of 1–5% for heavy 
to light ratio peptides with cut-off 0.01 and imported into 
Uniprot to generate fasta sequence files. A search for 
proteins with signal peptides ie classical secretory proteins 
(D cut off >0.5) was performed using SignaIP v.4.0. The 
dataset of secreted proteins exhibiting signal peptides 
was then used in PANTHERv.10 to identify significantly 
enriched (p<0.05) protein classes, molecular functions and 
biological processes.
Western blotting
Medium was concentrated using StrataClean resin 
(Agilent Technologies Ltd) and processed for western 
blotting as previously described [13] using antibodies to 
chemerin (R&D Systems), TIMP-1, TIMP-2 and MMP-1 
(R&D Systems).
Statistics
Results were calculated as mean ± standard error of 
means (SEM). Student t-test and ANOVA were performed 
on the data as appropriate with significance at p<0.05 
using Systat Software Inc. (London, UK) unless otherwise 
stated.
Abbreviations
CAMs, cancer associated myofibroblasts; CM, 
conditioned media; FDR, false discovery rate;.phorbol 
12-myristate 13-acetate, PMA; protein kinase C, 
stable isotope dynamic labeling of secretomes, SIDLS; 
protein kinase C, PKC; tissue inhibitor of matrix 
metalloproteinase, TIMP.
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